MA55611A - Association de chir99021 et d'acide valproïque pour traiter une perte auditive - Google Patents

Association de chir99021 et d'acide valproïque pour traiter une perte auditive

Info

Publication number
MA55611A
MA55611A MA055611A MA55611A MA55611A MA 55611 A MA55611 A MA 55611A MA 055611 A MA055611 A MA 055611A MA 55611 A MA55611 A MA 55611A MA 55611 A MA55611 A MA 55611A
Authority
MA
Morocco
Prior art keywords
chir99021
combination
hearing loss
valproic acid
treat hearing
Prior art date
Application number
MA055611A
Other languages
English (en)
Inventor
Moraye Bear
Jenna Herby
Ashley Hinton
Carl Lebel
Christopher Loose
Will Mclean
Original Assignee
Frequency Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frequency Therapeutics Inc filed Critical Frequency Therapeutics Inc
Publication of MA55611A publication Critical patent/MA55611A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA055611A 2019-04-08 2020-04-08 Association de chir99021 et d'acide valproïque pour traiter une perte auditive MA55611A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962831170P 2019-04-08 2019-04-08
US201962831169P 2019-04-08 2019-04-08
US201962831167P 2019-04-08 2019-04-08

Publications (1)

Publication Number Publication Date
MA55611A true MA55611A (fr) 2022-02-16

Family

ID=70476486

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055611A MA55611A (fr) 2019-04-08 2020-04-08 Association de chir99021 et d'acide valproïque pour traiter une perte auditive

Country Status (14)

Country Link
US (1) US20220175776A1 (fr)
EP (1) EP3952854A1 (fr)
JP (1) JP2022527391A (fr)
KR (1) KR20220007050A (fr)
CN (1) CN114340611A (fr)
AU (1) AU2020271067A1 (fr)
BR (1) BR112021020141A2 (fr)
CA (1) CA3136424A1 (fr)
IL (1) IL287094A (fr)
MA (1) MA55611A (fr)
MX (1) MX2021012258A (fr)
SG (1) SG11202111191YA (fr)
TW (1) TW202103692A (fr)
WO (1) WO2020210388A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240016766A1 (en) * 2020-11-26 2024-01-18 Alain Moussy Pharmaceutical composition for treatment of inner ear disorders through local administration in the tympanic area

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
CA2568028A1 (fr) 2004-05-24 2005-12-08 Auris Medical, Llc. Combine aspirateur otique et distributeur de medicament
EP2254572B1 (fr) 2008-02-07 2013-10-16 Massachusetts Eye & Ear Infirmary Composés stimulant l expression du gène atoh-1
EP2667881A4 (fr) 2011-01-24 2015-04-22 Univ Leland Stanford Junior Procédés de génération de cellules de l'oreille interne in vitro
JO3148B1 (ar) 2011-07-27 2017-09-20 Lilly Co Eli مركب مثبط لإشارات مسار notch
EP2606884A1 (fr) 2011-12-21 2013-06-26 Ecole Polytechnique Fédérale de Lausanne (EPFL) Inhibiteurs de la voie de signalisation notch et leur utilisation dans le traitement des cancers
JP6138928B2 (ja) 2012-06-01 2017-05-31 ライプニッツ−インスティテュート フュア アルテルスフォルシュング−フリッツ−リップマン−インスティテュート エー．ファウ．（エフエルイー） 医薬に使用されるｎｏｔｃｈシグナル伝達経路及び分泌の阻害物質
WO2014039781A1 (fr) 2012-09-07 2014-03-13 Massachusetts Eye & Ear Infirmary Traitement de la perte auditive
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
EP2897960B1 (fr) 2012-09-21 2016-08-03 Bristol-Myers Squibb Company Composés hétérocycliques tricycliques utilisables en tant qu'inhibiteurs du récepteur notch
EP2897954B1 (fr) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Composés fluoroalkyl-1,4-benzodiazépinones
CN104822665A (zh) 2012-09-21 2015-08-05 百时美施贵宝公司 用作Notch抑制剂的氟烷基和氟环烷基1,4-苯并二氮杂*酮化合物
CN104797569A (zh) 2012-09-21 2015-07-22 百时美施贵宝公司 取代的1,5-苯并二氮杂*酮化合物
JP2015534554A (ja) 2012-09-21 2015-12-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アルキル，フルオロアルキル−１，４−ベンゾジアゼピノン化合物
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
CN104968648A (zh) 2012-09-21 2015-10-07 百时美施贵宝公司 1,4-苯并二氮杂*酮化合物的前药
US9133126B2 (en) 2012-09-21 2015-09-15 Bristol-Myers Squibb Company Fluoroalkyl dibenzoazepinone compounds
US9572815B2 (en) 2013-03-15 2017-02-21 St. Jude Children's Research Hospital Methods and compositions of p27KIP1 transcriptional modulators
US20170314027A1 (en) 2014-08-06 2017-11-02 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
SG11201701844YA (en) 2014-10-08 2017-04-27 Agency Science Tech & Res Methods of differentiating stem cells into liver cell lineages
TWI625332B (zh) 2015-07-07 2018-06-01 美國禮來大藥廠 刻痕（ｎｏｔｃｈ）路徑傳訊抑制化合物
US20190093079A1 (en) 2016-03-02 2019-03-28 Frequency Therapeutics, Inc. Methods for controlled proliferation of stem cells / generating inner ear hair cells using gsk-3-alpha inhibitors
CN109311878B (zh) 2016-06-27 2022-05-24 豪夫迈·罗氏有限公司 作为γ-分泌酶调节剂的三唑并吡啶类化合物
EP3481829B1 (fr) 2016-07-08 2021-04-07 H. Hoffnabb-La Roche Ag Dérivés fusionnés de pyrimidine
EP3484884B1 (fr) 2016-07-14 2021-01-27 Hoffmann-La Roche AG Dérivés de pyrimidine fusionnés
AR109829A1 (es) 2016-09-29 2019-01-30 Hoffmann La Roche Derivados de piperidina puenteados
CN109476670B (zh) 2016-10-04 2022-06-28 豪夫迈·罗氏有限公司 二环杂芳基衍生物
AR110122A1 (es) 2016-11-08 2019-02-27 Hoffmann La Roche Fenoxitriazoles
KR20190098998A (ko) 2016-12-16 2019-08-23 파이프라인 테라퓨틱스, 아이엔씨. 달팽이관 시냅스질환의 치료 방법
WO2018118782A2 (fr) 2016-12-20 2018-06-28 Oligomerix, Inc. Nouveaux analogues de benzofuranes, de benzothiophènes et d'indoles qui inhibent la formation d'oligomères tau et leur procédé d'utilisation
CA3047730A1 (fr) 2016-12-20 2018-06-28 Oligomerix, Inc. Quinazolinones inhibant la formation d'oligomeres tau et methode d'utilisation
CA3048220A1 (fr) 2016-12-30 2018-07-05 Frequency Therapeutics, Inc. Composes 1h-pyrrole-2,5-dione et leurs procedes d'utilisation pour induire un auto-renouvellement de cellules de support souches/progenitrices
US10383881B2 (en) 2016-12-30 2019-08-20 Frequency Therapeutics, Inc. 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same
JP2020511486A (ja) 2017-03-24 2020-04-16 ノバルティス アーゲー イソオキサゾールカルボキサミド化合物及びその使用
WO2020037325A1 (fr) * 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions et procédés pour générer des cellules auditives par régulation à la hausse de pi3k
EP3837352A1 (fr) * 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions et méthodes pour générer des cellules ciliées par la régulation à la hausse de jag-1
CA3114113A1 (fr) * 2018-10-02 2020-04-09 Frequency Therapeutics, Inc. Compositions pharmaceutiques comprenant des agents therapeutiques otiques et procedes associes

Also Published As

Publication number Publication date
MX2021012258A (es) 2022-01-04
US20220175776A1 (en) 2022-06-09
SG11202111191YA (en) 2021-11-29
BR112021020141A2 (pt) 2021-12-21
EP3952854A1 (fr) 2022-02-16
IL287094A (en) 2021-12-01
JP2022527391A (ja) 2022-06-01
AU2020271067A1 (en) 2021-11-25
CN114340611A (zh) 2022-04-12
CA3136424A1 (fr) 2020-10-15
WO2020210388A1 (fr) 2020-10-15
KR20220007050A (ko) 2022-01-18
TW202103692A (zh) 2021-02-01

Similar Documents

Publication Publication Date Title
MA41013A (fr) Compositions comprenant des souches bactériennes
MA52232A (fr) Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer
MA41060A (fr) Compositions comprenant des souches bactériennes
MA55434B1 (fr) Compositions comprenant des souches bactériennes
MA41010A (fr) Compositions comprenant des souches bactériennes
MA49628A (fr) Processus pour la purification de l'acide hyaluronique
MA45798A (fr) Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
MA44737A (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
MA41411B1 (fr) Compositions dispersibles
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
MA53828A (fr) Compositions et méthodes pour le traitement d'infections pathogènes dans des plantes
AU2017260532A1 (en) Methods and devices for preparation of ultrasound contrast agents
MA50406B1 (fr) Inhibiteurs pyrazole de magl
MA55611A (fr) Association de chir99021 et d'acide valproïque pour traiter une perte auditive
MA42614A (fr) Dérivés d'acide 5-(n-benzyl tétrahydroisoquinolin-6-yl) pyridin-3-yl-acétique utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques
WO2017077528A3 (fr) Procédés et compositions pharmaceutiques pour le traitement d'inflammations pulmonaires
MA54522A (fr) Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire
MA54873A (fr) Compositions et méthodes pour le traitement de troubles neurocognitifs
EP4017880A4 (fr) Utilisation de brazikumab pour traiter la maladie de crohn
MA41142A (fr) Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
MA55093A (fr) Méthodes et compositions pour le traitement du cancer
MA46712A (fr) Combinaisons d'inhibiteurs de fgfr4 et de chélateurs de l'acide biliaire
MA50575A (fr) Préparation d'acide phosphorique